Get the Stockscreener App
3.57
4.29%
-0.16
After Hours:
3.58
0.01
+0.28%
Scynexis Inc stock is traded at $3.57, with a volume of 103.76K.
It is down -4.29% in the last 24 hours and down -7.27% over the past month.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
See More
Previous Close:
$3.73
Open:
$3.73
24h Volume:
103.76K
Relative Volume:
1.51
Market Cap:
$35.45M
Revenue:
$20.34M
Net Income/Loss:
$-24.52M
P/E Ratio:
-0.9983
EPS:
-3.5761
Net Cash Flow:
$-5.92M
1W Performance:
-8.34%
1M Performance:
-7.27%
6M Performance:
-44.22%
1Y Performance:
-38.88%
1-Day Range:
$3.53
$3.915
1-Week Range:
$3.53
$4.22
52-Week Range:
$3.53
$10.48
Scynexis Inc Stock (SCYX) Company Profile
Name
Scynexis Inc
Sector
Phone
201-884-5485
Address
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
3.57 | 37.04M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-21 | Initiated | Guggenheim | Buy |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-18 | Upgrade | Needham | Hold → Buy |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-10-17 | Initiated | ROTH Capital | Buy |
| May-09-17 | Downgrade | Needham | Buy → Hold |
| Mar-03-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-20-16 | Initiated | H.C. Wainwright | Buy |
| Oct-07-16 | Upgrade | WBB Securities | Buy → Strong Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Aug-17-16 | Initiated | Guggenheim | Buy |
| Aug-09-16 | Reiterated | Needham | Buy |
| Aug-09-16 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Mar-28-16 | Initiated | Brean Capital | Buy |
| Dec-29-15 | Initiated | WBB Securities | Speculative Buy |
| Nov-16-15 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-10-15 | Initiated | Needham | Buy |
| May-29-14 | Initiated | Canaccord Genuity | Buy |
| May-29-14 | Initiated | RBC Capital Mkts | Outperform |
View All
Scynexis Inc Stock (SCYX) Latest News
SCYNEXIS Inc (SCYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
SCYNEXIS Inc (SCYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView
SCYNEXIS, Inc. Revenue Breakdown – LSE:0L49 - TradingView
SCYNEXIS Inc (SCYX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SCYNEXIS (SCYX) Slides 2.35% as Biotech Stock Tests Key Support LevelInsider Buying Alerts - dars.gov.et
Federated Hermes (SCYX) group discloses 4.03% Scynexis stake in amended 13G - Stock Titan
FEDERATED HERMES, INC. Acquires 55,207 Shares of SCYNEXIS Inc - GuruFocus
Federated Hermes (SCYX) files 13G/A showing 55,207 shares (4.45%) - Stock Titan
Scynexis Deadline Alert - TMX Newsfile
Enterprise value to EBIT forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to EBIT forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
SCYNEXIS (NASDAQ:SCYX) Is In A Strong Position To Grow Its Business - Sahm
Form DEF 14A Scynexis Inc For: 2 July By Investing.com - Investing.com Nigeria
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained - TipRanks
Form 4 Scynexis Inc For: 30 June By Investing.com - Investing.com Nigeria
SCYNEXIS (SCYX) director receives new RSU and stock option grants - Stock Titan
SCYNEXIS (NASDAQ: SCYX) director gets RSU and option awards - Stock Titan
SCYNEXIS (SCYX) director Armando Anido granted stock units and options - Stock Titan
SCYNEXIS (SCYX) director receives new stock and option awards - Stock Titan
SCYNEXIS (SCYX) director Ann Hanham receives stock and option grants - Stock Titan
Enterprise value to revenue forward of SCYNEXIS, Inc. – FWB:135 - TradingView
Scynexis (SCYX) Launches Phase 1 Study for SCY-770 in Kidney Dis - GuruFocus
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYNEXIS Inc. (SCYX) Q1 2026 Earnings: Wider-than-Expected Loss on No Reported Revenue; Stock Rises 5.17%EBITDA Analysis - dars.gov.et
Enterprise value to revenue forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Enterprise value to revenue forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to book forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to earnings forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Price to sales forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to book forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – NASDAQ:SCYX - TradingView
Price to sales forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Enterprise value to EBITDA forward of SCYNEXIS, Inc. – GETTEX:135 - TradingView
SCYNEXIS (SCYX) Edges Higher as Support Holds, Resistance AwaitsRetracement Entry - dars.gov.et
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes - TipRanks
SCYNEXIS (SCYX) expands authorized stock and registers 87M shares for resale - Stock Titan
SCYNEXIS Inc (SCYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
SCYNEXIS, Inc. Actuals & Estimates (NASDAQ:SCYX) - TradingView
SCYX Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXis (SCYX) Surges 6.6% – Testing Key Resistance at $4.25Low Beta Factor - dars.gov.et
SCYNEXIS Inc (SCYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SCYNEXIS Inc (SCYX) Institutional Confidence - TradingKey
SCYNEXIS Inc (SCYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SCYNEXIS Inc (SCYX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com
SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueEPS Revision Trend - dars.gov.et
SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo
Scynexis Inc Stock (SCYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):